The Japan Marrow Donor Program (JMDP), established in 1991, has continued to grow in its capacity to facilitate unrelated bone marrow (BMT) and peripheral blood stem cell transplantation (PBSCT) for the past 25 years in Japan. The current donor pool is 463,465 (as of 31 December 2016) and 20,237 transplants were performed with the help of the Japanese Red Cross, government, and supporters. As JMDP introduced PBSCT in 2010, the vast majority of transplants are BMT. All donors are fully typed for HLA-A, B, C, and DR. The peak age of registered donors is around 40 years. The 8/8 HLAmatched donors are found in our registry for 96% of the patients and 54% of the patients receive a transplant. The median time between the initiation of donor search and the transplantation is approximately 122 days. The median interval between the initiation of donor search and identification of the first potential donor is 40 days. The most common diseases for which unrelated BMT/PBSCT is indicated are acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS), and malignant lymphoma. In recent years we have seen a marked increase in elderly patients who received BMT.
Introduction
Bone marrow transplantation and peripheral blood stem cell transplantation from unrelated donors (ur-BMT and ur-PBSCT) are potentially life-saving treatments for patients with hematological malignancies (such as leukemia and lymphoma) and other disorders (such as bone marrow failure, immunodeficiency, and inborn errors of metabolism) who do not have a donor in their family. The core of a donor registry is the presence of altruistic donors who are willing to donate their bone marrow (BM) or PBSC. The Japan Marrow Donor Program (JMDP) is a nonprofit organization in Japan that assists patients in need of unrelated bone marrow or peripheral blood stem cells to find suitable donors. It was established in 1991 by the initiative of the Ministry of Health, Labour, and Welfare of Japan. In 2014, the legislative framework of JMDP was stipulated to be the sole organization facilitating ur-BMT and ur-PBSCT. The current size of the donor pool, as of 31 December 2016, is 463,465. In the past 25 years, we have facilitated more than 20,237 ur-BM /ur-PBSC transplantations.
Structure of organization
The mission of JMDP is to impartially and effectively facilitate ur-BMT and ur-PBSCT for as many patients needing hematopoietic stem cell transplantation as possible, with a strong emphasis on donor safety (Fig. 1 ). For this purpose, JMDP operates donor recruitment and also the coordination of donors and patients. JMDP has a central office in Tokyo and 7 regional branch offices which serve as donor centers covering various areas throughout Japan. The executive board is responsible for the administration of JMDP and several standing committees serve to deliberate specific issues including donor safety, medical affairs, human leukocyte antigen (HLA) testing, data management, international collaboration, promotion of public relation, and the ethics related to BMT and PBSCT. The members of the standing committees include transplant physicians, anesthesiologists, transfusion physicians, nurses, Japanese Red Cross (JRC) staff, lawyers, and volunteers. JMDP cooperates closely with national and local governments, JRC, transplant centers, collection centers, transplant physicians, the Japan Society for Hematopoietic Cell Transplantation (JSHCT), the Japanese Data Center for Blood and Marrow Transplantation (JDCHCT), and volunteer supporters that are indispensable to achieve our goals. The donors are typed for HLA-A, B, C, and DR by JRC and the data are stored in the central computer. There are 185 collection and transplant centers, and 94 PBSC collection centers. All PBSC collection centers also collect BM. All of the centers have been certified by JMDP and JSHCT. The age and gender distribution of our donor pool illustrates that the peak age of registered donors is around 40 years for both males and females (Fig. 2) . Although the ratio of male to female donors for each age group is nearly equal, there are slightly more female donors under the age of 40 years and slightly more male donors over the age of 45 years. We are concerned by the fact that this peak seems to move to the right every year, thus further increasing older donors. Therefore, it is crucial for us to make a peak age shift to the left by recruiting younger donors and retaining them in our donor pool. Several approaches are now underway to achieve these goals.
Donor recruitment and patient registration
Patients are registered through a search request by their transplant physicians after HLA typing is obtained. Trends in patient registration are shown in Fig. 3 . There has been a steady growth in the number of patients who request ur-BMT/ur-PBSCT. It is notable that the increase is primarily due to the rising number of older patients (50 years or older), while the number of younger patients (age 16-49) remains rather constant and the number of children (age 0-15 years) has been gradually decreasing in recent years. A stagnation in the absolute number of search is noted since 2014. It may be speculated that some patients who have relapsed after BMT go directly to cord blood or haploidentical transplantation without registering to JMDP. Declining number of transplantation in children may be due to the decrease in the number of children in population and to the improvement of chemotherapy for childhood leukemia.
Coordination (matching process) and collection of stem cells
Of the patients, 96% are able to find at least one 8/8 HLAmatched donor with the current donor pool of 463,465. It is notable that this probability is very high compared to the 75% who find an optimal donor for whites of European descent in the National Marrow Donor Program (NMDP) in the United States [1] ; perhaps this difference is based on the genetic homogeneity of the Japanese population. The median time between the initiation of donor search and the transplantation is approximately 122 days. The median interval between the initiation of donor search and the identification of a first potential donor is around 40 days; several procedures, such as affirmation of the donor's commitment, confirmatory HLA typing, and careful medical examination of potential donors, are mandatory steps before donation. Despite our effort, this 122-day interval has not changed for the past 10 years, and it seems to be longer than that of NMDP [2] . We assessed the consequences of the coordination process (matching process) from the patient's side. In 2015, 2297 patients made a search request, and for 2201 of them (96%) HLA fullmatched donors were found. By the end of 2016, 1237 patients (54%) received HLA full match or one-HLA mismatch transplants. However, 1060 patients (46%), including 96 patients with no matched donors in JMDP, were not able to receive BMT/PBSCT, due to either death, progressive disease, or they opted to receive cord blood transplantation (249) or related haploidentical BMT/PBSCT (113). Some patients were still in the process of coordination as of 31 December 2016 (Fig. 4) . The transplant rates according to primary diagnosis range from 49% to 61% (Table 1) . In general, the coordination process, which begins immediately after HLA-matched donors are identified, consists of several steps as listed above. The outcome of the coordination process in 2015 from the viewpoint of the donor was as follows: starting with 28,363 HLA-matched potential donors (100%), only 4.5% (1265) of potential donors were able to donate BM/PBSC. From our experience, the biggest loss of potential donors occurs in an early stage of the coordination process before the medical checkup and confirmatory HLA typing: only 18% of potential donors reach the confirmatory HLA typing step. The reasons for terminating the coordination process are exclusively based on the donor (97%): both non-medical (66%) and medical reasons (31%). Non-medical reasons include "too busy at this time", "no reply to the request", and "lack of family's consent". Medical reasons are "currently under medical treatment", "past medical history after donor figure  online) registration", and" pregnancy/child birth". The entire process of BM donation for the donor takes, on average, about 7 days in total; the donor is not allowed to work during these 7 days. To compensate for the donor's effort, some corporations have implemented a policy giving the employee a paid holiday when they serve as a donor. Some cities and towns have begun a program to provide the donor with a reward. We believe that these donor-friendly measures may encourage BM/PBSC donations. A unique feature of JMDP is that the informed consent of both the donor and his or her family are mandatory before donation. Lack of family's consent (parents or spouse) appears to be the primary reason for coordination process termination in young donors (20-29 years old). Medical reasons for terminating the coordination process in early stage include non-communicable diseases, such as hypertension, and liver function test abnormalities. It is not surprising to encounter some incidental medical problems, as the majority of our donor pool consists of middle-aged persons, as shown in Fig. 2 . While 18% (5212) of donors reach confirmatory HLA typing, only 4.5% (1265) of potential donors were able to donate. This is because on average three HLA-matched potential donors are found for one patient. Donors with some abnormalities in blood tests or in electrocardiography or respiratory function tests are also excluded. The lack of family's consent plays a negative role here too. Of the 122 days of the complete coordination process, the time between the selection of the final donor and BM collection takes 78 days on average. This delay is mainly due to the limited availability of operation rooms for collection, and the shortage of anesthesiologists and hematologists.
Transplantation
The number of transplants facilitated by JMDP has increased over time (Fig. 5) . The upward trend has been, :03-C*14:03-DRB1*13:02. We limit the maximum donations to only two times. Our preliminary analysis of 820 second donations suggest that the second donation caused no significant influence on donor's health but resulted in the lower yield of nucleated bone marrow cells [3] .
The ur-PBSCT was introduced in JMDP in 2010, and only 255 have been performed to date. This is one of the most striking differences between JMDP and other registries, including NMDP [4, 5] , ZKRD (Zentrales Knochenmarkspender Register Deutschland) [6] , and Chinese Morrow Donor Program (CMDP), where PBSCT plays a dominant role.
The most common diseases for which ur-BMT/ur-PBSCT is indicated are acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS), and malignant lymphoma. This is consistent with the worldwide trend as reported recently by The Worldwide Network of Blood and Marrow Transplantation [7] . Between 2000 and 2016, some changes were noted in the type of diseases for which BMT was performed (Fig. 6) . Chronic myelogenous leukemia (CML) accounted for 24% in 2000, but only 3% in 2016; the decline of BMT for CML is a result of the introduction of tyrosine kinase inhibitors. The percentage of MDS has increased from 9% in 2000 to 20% in 2016, reflecting the aging population. Another change is the marked increase in elderly patients who received BMT in 2016 compared to in 2000 (Fig. 7) ; the percentage of patients over the age of 50 years was only 9% in 2000, whereas it was 51% in 2016. This is due in part to the introduction of improved supportive care and the less invasive conditioning which is generally safe for elderly patients.
Adverse reactions to donors
Few adverse reactions are associated with BM donations. Most of the adverse reactions are mild, such as temporary backache and fatigue. There was no donor death. The common symptoms experienced by BM donors in NMDP also included back or hip pain and fatigue [8] . Of the 19,297 donors who donated bone marrow, 38 donors (0.2%) and 159 donors (0.8%) received liability insurance payment for residual disorders and hospital admission, respectively. Residual disorders included continued local pain and numbness of bone puncture sites. Insurance payments for hospital admission included intramuscular hematoma formation, ureter injuries due to catheterization, and teeth injuries caused by intubation for general anesthesia. The survey by the European Group for Blood and Marrow Transplantation (EBMT) reported 1 death and 12 severe adverse events such as myocardial infarction and arrhythmia in 27,770 allogeneic BMT performed from 1993 to 2005 in European countries [9] .
The death occurred in a family donor. In that report, severe adverse events were defined and restricted to any cardiovascular event or splenic rupture occurring within 30 days of donation and necessitating hospitalization. To date, we have not encountered such adverse events in our donors. 
International collaboration and scientific research
We have established a collaborative relationship with NMDP, Buddist Tzu Chi Stem Cells Center (BTCSCC, Taiwan), Korean Marrow Donor Program (KMDP), CMDP, and other registries, and thus donors are available for search through international collaboration.
As of yet however, our international cooperation has been very limited; only 1% of JMDP-facilitated transplantations were carried out internationally. In the past 25 years, we have received 120 BM from NMDP (25 provided to), 42 BM from BTCSCC (0 provided to), 20 BM from KMDP (194 provided to), and 3 BM from CMDP (0 provided to). These data may indicate that Japanese share, to some extent, the same HLA haplotype as Koreans. JMDP is a member of the World Marrow Donor Association (WMDA) since 1999 and has been accredited by the WMDA. Scientific research plays an important role in improving the outcome of ur-BMT. We have stored paired DNA samples of donors and patients to promote research for the past 23 years. These samples have been essential for many studies on HLA types and transplant-related complications, including graft failure, leukemia relapse, and acute/chronic graft-versus-host disease [10, 11] . The results of these studies have been useful to provide a rationale for an algorithm for donor selection by JMDP. The sample stock project has been transferred to JRC and JDCHCT since 2015.
Financial basis
The annual budget of JMDP (1.52 billion Japanese yen, approximately 13.8 million US$ in 2015) is dependent on funding from various sources: medical insurance (36%), government subsidy (30%), patients' fee (22%), and donations (13%). The patient's fee is the cost imposed on patients who receive ur-BMT or ur-PBSCT. The current patient's fee is 193,000 Japanese yen, about 1755 US$. Direct medical costs of BM/PBSC collection and transplantation are covered by our universal health coverage policy. However, the cost regarding donor's HLA typing, medical examination and admission, and donor's liability insurance premium are outside of the policy. We have a financial safety net for low-income patients who are unable to afford the patient fee. The cost of facilitating one ur-BMT/ur-PBSCT by JMDP, as roughly estimated by dividing the annual budget by the number of ur-BMT/ur-PBSCT, is approximately 1,200,000 Japanese yen, approximately 10,900US$. This includes all staff salaries and other operating expenses of JMDP.
Future perspectives
JMDP has been successful in promoting ur-BMT and ur-PBSCT. However, to further improve our performance, we must overcome several challenges. First, although 8/8 HLAmatched donors are found in our registry for 96% of the patients, only 54% of these patients are able to receive a transplant; this represents a huge gap. Although this gap may be very difficult to narrow given the voluntary donation scheme, JMDP is now attempting to reduce the gap as much as possible by shortening the search turnaround time. The ministry of Health, Labour, and Welfare of Japan has recently launched a core-transplant center project in which nine hospitals have been entrusted to speed up the coordination process throughout Japan. JMDP also expects that the introduction of ur-PBSCT will contribute to the shortening of the search turnaround time, as it does not require figure  online) operation rooms for collection and it lightens the donor burden. However, the utilization of ur-PBSCT remains low. This is in contrast to NMDP where PBSC surpassed BM as the stem cell source in the 4 years after the first use of PBST [5] . There are several reasons for the poor utilization of ur-PBSCT. The main reason is that the requirements for ur-PBSCT are very strict: donors must reside within 1 h of the collection center, and physicians should be present for the complete PBSC collection time. These precautions were set to ensure the safety of the donor during the introduction period of ur-PBSCT, but once sufficient experience is accumulated, such strict precautions may be lightened or may be no longer necessary.
Second, the recruitment and retention of young donors are imperative factors. The use of information communication technology (ICT) and social media may be useful for this purpose. There is also a need to increase the percentage of well-motivated donors.
Third, the financial basis of JMDP is rather fragile, as it partly depends on the patient's fee and also donations. The sum of donations is difficult to anticipate. We have encountered a deficit in recent years; more support from the public sector is needed.
